R&G Pharma Studies Co.,Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2008)

Organization Overview

First Clinical Trial
2013
NCT01944774
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

R&G Pharma Studies Co.,Ltd.

Active Ingredients

Drugs in Phase 2 Trials (5)

h002 (1 trial)

moxifloxacin (avelox) (1 trial)

nemonoxacin (1 trial)

sph3127 (1 trial)

tg-1000 (2 trials)

Drugs in Phase 1 Trials (2)

furaprevir (2 trials)

yimitasvir (1 trial)

Drugs in Other Trials (1)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Essential Hypertension (Phase 2)

Hypertension (Phase 2)

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 8